WTA to Require One-Time Genetic Sex Testing for Players

New Rules for WTA Competition

The Women’s Tennis Association will oblige every player on the WTA Tour to take a one‑time genetic sex test in order to compete. Starting Tuesday, athletes must submit a cheek swab, blood sample or saliva to check for the presence of the SRY gene, a marker on the Y chromosome linked to male development. A negative result is the sole pathway to participation; a positive finding triggers an additional medical evaluation before any clearance is granted. Refusal to be tested can lead to disciplinary measures, according to the signed agreement each player must complete.

How the Genetic Test Works

Under the updated eligibility policy, which rolls out in 2026, the SRY test is administered only once per athlete. Players are given three sample options—cheek swab, blood or saliva—providing flexibility in how the genetic material is collected. If the test detects the gene, the athlete proceeds to a further medical assessment to determine eligibility. This approach replaces the previous protocol that focused on hormone levels rather than genetic markers.

Comparison with Other Sports

The WTA’s move mirrors recent changes in other major sports governing bodies. World Athletics implemented a mandatory one‑time gene test for female category competitors starting in September 2025, while World Boxing approved the use of the SRY test in May 2025 for its women’s events. These parallel updates suggest a growing trend toward biological sex verification across international athletics. The shift also reflects ongoing discussions about fairness and the definition of eligibility in women’s competition.

What It Means for Players

For current and future WTA athletes, the new rule introduces a concrete medical checkpoint that could affect career trajectories. The requirement to sign a document acknowledging possible sanctions underscores the policy’s enforceability. While the previous framework allowed transgender women to compete after sustained testosterone reduction below 2.5 nmol/L for two years, no transgender players are currently active on the Tour. The WTA’s statement emphasizes equal opportunity and respectful implementation amid what it calls a sensitive and complex issue. Players will need to weigh the testing requirement against their personal and medical circumstances as the 2026 season approaches.